Man Group plc Acquires New Position in Agios Pharmaceuticals, Inc. $AGIO

Man Group plc acquired a new stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 124,466 shares of the biopharmaceutical company’s stock, valued at approximately $4,619,000. Man Group plc owned 0.21% of Agios Pharmaceuticals as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in AGIO. Sei Investments Co. increased its stake in shares of Agios Pharmaceuticals by 342.8% in the first quarter. Sei Investments Co. now owns 63,550 shares of the biopharmaceutical company’s stock worth $2,150,000 after acquiring an additional 49,198 shares during the last quarter. SCS Capital Management LLC acquired a new stake in Agios Pharmaceuticals during the second quarter valued at $22,743,000. State of New Jersey Common Pension Fund D acquired a new stake in Agios Pharmaceuticals during the fourth quarter valued at $1,291,000. GW&K Investment Management LLC grew its stake in Agios Pharmaceuticals by 41.5% in the fourth quarter. GW&K Investment Management LLC now owns 1,207,301 shares of the biopharmaceutical company’s stock valued at $32,863,000 after purchasing an additional 354,359 shares in the last quarter. Finally, Seven Fleet Capital Management LP purchased a new position in Agios Pharmaceuticals in the fourth quarter valued at about $864,000.

Insider Buying and Selling at Agios Pharmaceuticals

In related news, insider Sarah Gheuens sold 30,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $30.48, for a total value of $914,400.00. Following the transaction, the insider directly owned 54,645 shares of the company’s stock, valued at approximately $1,665,579.60. This trade represents a 35.44% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 5.40% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on AGIO. Citigroup raised their price target on Agios Pharmaceuticals from $46.00 to $52.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. Bank of America boosted their price target on Agios Pharmaceuticals from $40.00 to $46.00 and gave the company a “buy” rating in a research note on Tuesday, July 7th. TD Cowen upgraded Agios Pharmaceuticals to a “strong-buy” rating in a report on Monday, August 24th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Agios Pharmaceuticals in a research report on Wednesday, June 24th. Finally, Royal Bank Of Canada lifted their target price on shares of Agios Pharmaceuticals from $28.00 to $32.00 and gave the company a “sector perform” rating in a research note on Tuesday, July 7th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $41.25.

Agios Pharmaceuticals Price Performance

Agios Pharmaceuticals stock opened at $33.32 on Monday. Agios Pharmaceuticals, Inc. has a one year low of $22.24 and a one year high of $46.00. The company’s fifty day moving average price is $35.90 and its two-hundred day moving average price is $31.66. The company has a market capitalization of $1.99 billion, a price-to-earnings ratio of -4.75 and a beta of 0.58.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.65) by ($0.04). The company had revenue of $44.75 million during the quarter, compared to analyst estimates of $26.39 million. Agios Pharmaceuticals had a negative return on equity of 35.67% and a negative net margin of 418.24%. As a group, sell-side analysts anticipate that Agios Pharmaceuticals, Inc. will post -5.82 earnings per share for the current year.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.